MedPath

Prospective, Verification Study to Assess Condom Fit Across Polyurethane (PU) and Natural Rubber Latex (NRL) Condoms

Not Applicable
Recruiting
Conditions
Condom Use
Registration Number
NCT06777797
Lead Sponsor
Reckitt Benckiser Healthcare (UK) Limited
Brief Summary

The investigation is to explore condom experience in terms of comfort and fit across a range of condom sizes and materials.

Detailed Description

In this investigation, 4 Polyurethane (PU) condom variants and 4 Natural Rubber Latex (NRL) condom variants will be tested by participants to explore condom experience.

Recruitment & Eligibility

Status
RECRUITING
Sex
Male
Target Recruitment
224
Inclusion Criteria
  1. Signed written informed consent before participation in the clinical investigation.
  2. Cisgender male, aged 18 - 55 years.
  3. In the opinion of Investigator, experienced user of condoms who use condoms to prevent pregnancies and / or contracting STIs.
  4. Able and willing to achieve a penile erection following self-stimulation.
  5. Able and willing to masturbate with a PU or NRL condom on.
  6. Agree to use only lubricant provided by the study for use with IMDs, if required.
  7. Agree not to wear any genital piercing jewelry while using the study condoms.
  8. Agree not to use sex toys, consume alcohol or use drugs intended to enhance or diminish sexual response when using study condoms.
  9. Agree to perform erected penis size measurement at site and at home.

Key

Exclusion Criteria
  1. Participants with known trouble attaining or maintaining an erection.
  2. Participants presenting clinically abnormal findings on the penis that in the opinion of the investigator can affect the study outcome.
  3. Participants with an allergy or sensitivity to the ingredients of the test products, including the test condoms or any lubrication products provided.
  4. Use of any topical medications applied to the penis between screening and visit 3.
  5. Participants with diagnosed or suspected erectile dysfunction.
  6. Participants with a history of prostatectomy.
  7. Participants with a history of urethral surgery.
  8. Participants with any other congenital or acquired genital abnormalities (e.g. peyronies disease, hypospadias, intersex, phimosis, penile cancer).
  9. Psychiatric conditions that might limit the participation in the clinical investigation and/or that lead to the assumption that the ability to completely understand the consequences of consent is missing.
  10. Participants with any medical condition in the opinion of the investigator which poses a risk to the participant or is detrimental to the objectives of the clinical investigation.
  11. Participants who should not participate in the clinical investigation for any other reason as judged by the investigator.
  12. Participation in a pharmaceutical trial with investigational products or in a clinical investigation with another medical device within the last 30 days prior to the visit 2 (day 1) and / or during this clinical investigation.
  13. Employees of the investigation sites who are directly involved in this clinical investigation or employees of the sponsor's company.

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
The exploration of condom experience across a range of sizes and materials6 weeks condom use period (intervention duration)

Participants will measure their penis size at screening and will be assigned to pre-defined groups. The endpoint is the exploration of condom experience across a range of materials and sizes within each group. Participants will evaluate the condoms over a period of 6 weeks and rate their condom experience through subject perceived questionnaires using the following scales:

1. Disagree, somewhat disagree, neither agree nor disagree, agree, strongly agree;

2. 1-10 with 1 being extremely dissatisfied and 10 being extremely satisfied.

Secondary Outcome Measures
NameTimeMethod
Examine whether the preferred condom variant is the same for both PU and NRL condoms.6 weeks condom use period (intervention duration)

The endpoint is the evaluation of the correspondence of preferred condom variant for PU and NRL condoms. The endpoint is collected over a period of 6 weeks on different condom types and variants by means of subject perceived questionnaires which participants will rate their condom preference using the following scales:

1. Disagree, somewhat disagree, neither agree nor disagree, agree, strongly agree;

2. 1-10 with 1 being extremely dissatisfied and 10 being extremely satisfied.

Trial Locations

Locations (1)

SGS proderm GmbH

🇩🇪

Schenefeld, Germany

© Copyright 2025. All Rights Reserved by MedPath